Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Results presented at oncology conference in Chicago show Galleri test failed to reduce late-stage cancer diagnoses A blood test for more than 50 types of cancer that was billed as the holy grail of oncology has failed to achieve its main objective in a major clinical trial, according to data presented at the world’s largest cancer conference. The goal of the study involving 142,000 NHS patients in the UK was to assess whether adding the multi-cancer early detection test Galle
A large-scale clinical trial involving 142,000 patients within the UK's National Health Service has concluded that the Galleri blood test did not meet its primary objective. The study aimed to determine if this multi-cancer early detection test, when used alongside existing screening methods, could successfully identify cancers at earlier, more treatable stages. However, the results, presented at a major oncology conference, indicated that the test did not significantly reduce the number of late-stage cancer diagnoses.
This outcome is significant because it questions the immediate effectiveness of a highly anticipated blood test in improving early cancer detection rates within a national healthcare system.
📌 Kaynak
Bu özet Guardian World kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →